Le Lézard
Classified in: Health
Subjects: TDS, PET, ANW, FVT

Petco to Participate in the 30th Annual Goldman Sachs Global Retailing Conference


SAN DIEGO, Sept. 8, 2023 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (Nasdaq: WOOF), today announced that Ron Coughlin, Chairman and Chief Executive Officer, will participate in a fireside chat at the 30th Annual Goldman Sachs Global Retailing Conference on September 13 at 3:55 p.m. Eastern Standard Time.

The live audio webcast will be available via the Company's investor relations page at ir.petco.com. A replay of the webcast will be archived on the Company's website through September 27, 2023.

About Petco, The Health + Wellness Co.:
Founded in 1965, Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. We've consistently set new standards in pet care while delivering comprehensive pet wellness products, services and solutions, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 pet care centers across the U.S., Mexico and Puerto Rico, which offer merchandise, companion animals, grooming, training and a growing network of on-site veterinary hospitals and mobile veterinary clinics. Our complete pet health and wellness ecosystem is accessible through our pet care centers and digitally at petco.com and on the Petco app. In tandem with Petco Love, a life-changing organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we've helped find homes for nearly 7 million animals.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact. Although Petco believes that the expectations and assumptions reflected in these statements are reasonable, there can be no assurance that these expectations will prove to be correct. Forward-looking statements are subject to many risks and uncertainties, including the risk factors that Petco identifies in its Securities and Exchange Commission filings, and actual results may differ materially from the results discussed in such forward-looking statements. Petco undertakes no duty to update publicly any forward-looking statement that it may make, whether as a result of new information, future events or otherwise, except as may be required by applicable law, regulation or other competent legal authority.

SOURCE Petco - Investor Relations


These press releases may also interest you

at 10:52
May is Healthy Vision Month, and Eyemart Express is taking the opportunity to shed light on an often overlooked yet prevalent issue: dry eyes. Approximately 50.2 million Americans suffer from dry eyes, and that number is increasing with our growing...

at 10:49
In a significant move to enhance its services and expertise, Mobile Health, a leading occupational health provider, proudly announces the addition of a Certified Occupational Hearing Conservationist (COHC) to its team....

at 10:45
DermCare Management, a leader in specialized dermatology and cosmetic surgery practice management services, proudly announces two new practice acquisitions in Texas, bringing the total number of practice locations to 70.  ...

at 10:40
Results of the first-ever cost-effectiveness study of a Factor XI inhibitor were presented today during sessions of the Professional Society for Health Economics and Outcomes Research (ISPOR) annual meeting. The analysis indicates that abelacimab...

at 10:30
According to a new market research report titled, 'Remote Patient Monitoring Market by Product ([Blood Glucose, Respiratory, Blood Pressure, Fetal, Weight Monitoring] [Wearable, Portable, Benchtop]) Application (Diabetes, Oncology, Cardiovascular,...

at 10:30
Injectable Drug Delivery Market in terms of revenue was estimated to be worth $754.5 billion in 2024 and is poised to reach $1139.4 billion by 2029, growing at a CAGR of 8.6% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...



News published on and distributed by: